Eli Lilly and Company (LLY) : Eli Lilly and Company (LLY) had a healthy money flow of $18.73 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $55.08 million, whereas, investors only sold shares worth $36.35 million on downticks. The stock closed the day with an up-down ratio of 1.52.The money flow in the block trades to the tune of $22.55 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $26.67 million worth of transactions were on upticks. A paltry $4.12 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 6.47. Eli Lilly and Company (LLY) stock slid $0.27 intraday and traded at 79.95, a change of -0.34% over previous days close. However, for the week, the company shares are 0.36% compared to previous weeks close.
Eli Lilly and Company is up 4.23% in the last 3-month period. Year-to-Date the stock performance stands at -3.82%. Shares of Eli Lilly and Company rose by 1.02% in the last five trading days and 7.68% for the last 4 weeks. In a related news, The officer (Chief Eth/Cmpl Ofcr & SVP, ERM), of Lilly Eli & Co, Barnes Melissa S had unloaded 992 shares at $73.77 per share in a transaction on June 10, 2016. The total value of transaction was $73,180. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (NYSE:LLY): On Mondays trading session , Opening price of the stock was $80.37 with an intraday high of $80.59. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $79.855. However, the stock managed to close at $79.95, a loss of 0.34% for the day. On the previous day, the stock had closed at $80.22. The total traded volume of the day was 3,087,620 shares.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.